Imatinib mesylate [clinicaltrials_resource:a4ce0d6db58fc2c8deb16b544ca3c933]
intervention [clinicaltrials_vocabulary:intervention]
Imatinib mesylate [clinicaltrials_resource:a4ce0d6db58fc2c8deb16b544ca3c933]
Bio2RDF identifier
a4ce0d6db58fc2c8deb16b544ca3c933
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a4ce0d6db58fc2c8deb16b544ca3c933
arm group [clinicaltrials_vocabulary:arm-group]
intervention desc [clinicaltrials_vocabulary:intervention-desc]
For Ph+ acute lymphoblastic le ...... mg for >18 years on Days 1-16.
intervention name [clinicaltrials_vocabulary:intervention-name]
Imatinib mesylate
other name [clinicaltrials_vocabulary:other-name]
Gleevec(R)
identifier
clinicaltrials_resource:a4ce0d6db58fc2c8deb16b544ca3c933
title
Imatinib mesylate
@en
type
label
Imatinib mesylate [clinicaltrials_resource:a4ce0d6db58fc2c8deb16b544ca3c933]
@en